{"filing":{"accession_number":"0001193125-26-302281","cik":"0001506184","ticker":"PRRUF","company_name":"IMMUTEP Ltd","form":"6-K","filing_date":"2026-07-13","report_date":null,"primary_document":"d105704d6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1506184/000119312526302281/d105704d6k.htm"},"events":[{"id":17692,"run_id":15858,"accession_number":"0001193125-26-302281","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"This is a clinical update press release announcing mature overall survival data from the INSIGHT-003 Phase I trial (mOS 30.9 months in 1L NSCLC) and a root cause analysis update for the discontinued TACTI-004 Phase III trial. While not a traditional earnings release of financial results, it discloses material clinical trial outcomes for the company's lead candidate eftilagimod alfa that would significantly affect investor assessment of the drug's development prospects and commercial potential. The positive INSIGHT-003 data and the investigation into TACTI-004's failure represent key clinical milestones material to the registrant's pipeline and strategy.","company_name":"IMMUTEP Ltd","ticker":"PRRUF","filing_date":"2026-07-13","form":"6-K","submitted_at":null,"items":[{"id":16259,"accession_number":"0001193125-26-302281","item_number":"EX-99.1","item_title":"d105704dex991.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This is a clinical update press release announcing mature overall survival data from the INSIGHT-003 Phase I trial (mOS 30.9 months in 1L NSCLC) and a root cause analysis update for the discontinued TACTI-004 Phase III trial. While not a traditional earnings release of financial results, it discloses material clinical trial outcomes for the company's lead candidate eftilagimod alfa that would significantly affect investor assessment of the drug's development prospects and commercial potential. The positive INSIGHT-003 data and the investigation into TACTI-004's failure represent key clinical milestones material to the registrant's pipeline and strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-14T10:04:45.358286+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16259,"accession_number":"0001193125-26-302281","item_number":"EX-99.1","item_title":"d105704dex991.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This is a clinical update press release announcing mature overall survival data from the INSIGHT-003 Phase I trial (mOS 30.9 months in 1L NSCLC) and a root cause analysis update for the discontinued TACTI-004 Phase III trial. While not a traditional earnings release of financial results, it discloses material clinical trial outcomes for the company's lead candidate eftilagimod alfa that would significantly affect investor assessment of the drug's development prospects and commercial potential. The positive INSIGHT-003 data and the investigation into TACTI-004's failure represent key clinical milestones material to the registrant's pipeline and strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-14T10:04:45.358286+00:00","company_name":"IMMUTEP Ltd","ticker":"PRRUF","filing_date":"2026-07-13"}]}